OOIR: Observatory of International Research

Papers

(The TQCC of JAMA Neurology is 21. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-04-01 to 2024-04-01.)

Article	Citations
Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease 2019 in Wuhan, China	4769
Neuropathogenesis and Neurologic Manifestations of the Coronaviruses in the Age of Coronavirus Disease 2019	694
Risk of Ischemic Stroke in Patients With Coronavirus Disease 2019 (COVID-19) vs Patients With Influenza	423
Clinical Characteristics and Outcomes in Patients With Coronavirus Disease 2019 and Multiple Sclerosis	348
Magnetic Resonance Imaging Alteration of the Brain in a Patient With Coronavirus Disease 2019 (COVID-19) and Anosmia	297
Neurologic and Radiographic Findings Associated With COVID-19 Infection in Children	289
Neurologic Involvement in Children and Adolescents Hospitalized in the United States for COVID-19 or Multisystem Inflammatory Syndrome	270
Burden of Neurological Disorders Across the US From 1990-2017	257
Contribution of Relapse-Independent Progression vs Relapse-Associated Worsening to Overall Confirmed Disability Accumulation in Typical Relapsing Multiple Sclerosis in a Pooled Analysis of 2 Randomize	253
Amyloid-Related Imaging Abnormalities in 2 Phase 3 Studies Evaluating Aducanumab in Patients With Early Alzheimer Disease	241
Positron Emission Tomography Imaging With [¹⁸F]flortaucipir and Postmortem Assessment of Alzheimer Disease Neuropathologic Changes	240
Assessment of Systemic Delivery of rAAVrh74.MHCK7.micro-dystrophin in Children With Duchenne Muscular Dystrophy	227
Association of Delirium With Long-term Cognitive Decline	227
Assessment of Endovascular Treatment for Acute Basilar Artery Occlusion via a Nationwide Prospective Registry	220
Outcomes and Risk Factors Associated With SARS-CoV-2 Infection in a North American Registry of Patients With Multiple Sclerosis	218
Ambroxol for the Treatment of Patients With Parkinson Disease With and Without Glucocerebrosidase Gene Mutations	209
Differences Between Plasma and Cerebrospinal Fluid Glial Fibrillary Acidic Protein Levels Across the Alzheimer Disease Continuum	204
Head-to-Head Comparison of 8 Plasma Amyloid-β 42/40 Assays in Alzheimer Disease	194
Safety, Efficacy, and Feasibility of Intranasal Insulin for the Treatment of Mild Cognitive Impairment and Alzheimer Disease Dementia	193
Associations of Plasma Phospho-Tau217 Levels With Tau Positron Emission Tomography in Early Alzheimer Disease	181
The Coronavirus Disease 2019 Crisis as Catalyst for Telemedicine for Chronic Neurological Disorders	170
Safety, Tolerability, and Efficacy of Viltolarsen in Boys With Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping	168
Association of Factors With Elevated Amyloid Burden in Clinically Normal Older Individuals	167
Dose-Ranging Effect of Adjunctive Oral Cannabidiol vs Placebo on Convulsive Seizure Frequency in Dravet Syndrome	163
Association of Apolipoprotein E ε4 With Medial Temporal Tau Independent of Amyloid-β	152

Assessment of ¹⁸F-PI-2620 as a Biomarker in Progressive Supranuclear Palsy	147
Accuracy of Tau Positron Emission Tomography as a Prognostic Marker in Preclinical and Prodromal Alzheimer Disease	146
Longitudinal Associations of Blood Phosphorylated Tau181 and Neurofilament Light Chain With Neurodegeneration in Alzheimer Disease	144
Novel Alzheimer Disease Risk Loci and Pathways in African American Individuals Using the African Genome Resources Panel	143
Identification of Risk Loci for Parkinson Disease in Asians and Comparison of Risk Between Asians and Europeans	140
Add-on Cannabidiol Treatment for Drug-Resistant Seizures in Tuberous Sclerosis Complex	140
The Spectrum of Neurologic Disease in the Severe Acute Respiratory Syndrome Coronavirus 2 Pandemic Infection	139
Noncontrast Computed Tomography vs Computed Tomography Perfusion or Magnetic Resonance Imaging Selection in Late Presentation of Stroke With Large-Vessel Occlusion	136
Five-Year Extension Results of the Phase 1 START Trial of Onasemnogene Abeparvovec in Spinal Muscular Atrophy	136
Association Between Cardiovascular Disease and Long-term Exposure to Air Pollution With the Risk of Dementia	133
Ponesimod Compared With Teriflunomide in Patients With Relapsing Multiple Sclerosis in the Active-Comparator Phase 3 OPTIMUM Study	133
Diagnostic Performance of RO948 F 18 Tau Positron Emission Tomography in the Differentiation of Alzheimer Disease From Other Neurodegenerative Disorders	132
Humoral and T-Cell Response to SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis Treated With Ocrelizumab	132
Global Prevalence of Young-Onset Dementia	130
One-Year Trajectory of Cognitive Changes in Older Survivors of COVID-19 in Wuhan, China	128
Clinical Effects of the Self-administered Subcutaneous Complement Inhibitor Zilucoplan in Patients With Moderate to Severe Generalized Myasthenia Gravis	127
Positive Predictive Value of Myelin Oligodendrocyte Glycoprotein Autoantibody Testing	126
Clinical Presentation, Investigation Findings, and Treatment Outcomes of Spontaneous Intracranial Hypotension Syndrome	123
Assessment of Brain Injury Using Portable, Low-Field Magnetic Resonance Imaging at the Bedside of Critically Ill Patients	120
Effect of High-frequency (10-kHz) Spinal Cord Stimulation in Patients With Painful Diabetic Neuropathy	118
Effect of Endovascular Treatment With Medical Management vs Standard Care on Severe Cerebral Venous Thrombosis	116
Comparison of Plasma Phosphorylated Tau Species With Amyloid and Tau Positron Emission Tomography, Neurodegeneration, Vascular Pathology, and Cognitive Outcomes	114
Effect of Levetiracetam on Cognition in Patients With Alzheimer Disease With and Without Epileptiform Activity	111
Global Prevalence and Incidence of Tinnitus	109
Prevalence and Clinical Phenotype of Quadruple Misfolded Proteins in Older Adults	108
Expanded Clinical Phenotype, Oncological Associations, and Immunopathologic Insights of Paraneoplastic Kelch-like Protein-11 Encephalitis	108
Skin α-Synuclein Aggregation Seeding Activity as a Novel Biomarker for Parkinson Disease	107
Comparison of Integrated Outpatient Palliative Care With Standard Care in Patients With Parkinson Disease and Related Disorders	106
Proposal for Updated Nomenclature and Classification of Potential Causative Mechanism in Patent Foramen Ovale–Associated Stroke	104
Functional Outcomes Over the First Year After Moderate to Severe Traumatic Brain Injury in the Prospective, Longitudinal TRACK-TBI Study	104
Association of Short and Long Sleep Duration With Amyloid-β Burden and Cognition in Aging	101
Association Between SARS-CoV-2 Infection and Immune-Mediated Myopathy in Patients Who Have Died	100
Association of Time Since Injury to the First Clinic Visit With Recovery Following Concussion	98
Assessment of the Predictive Value of Outpatient Smartphone Videos for Diagnosis of Epileptic Seizures	97
Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum	97
Treatment Escalation vs Immediate Initiation of Highly Effective Treatment for Patients With Relapsing-Remitting Multiple Sclerosis	93
Use and Safety of Immunotherapeutic Management of N-Methyl-d-Aspartate Receptor Antibody Encephalitis	92
Identification of Candidate Parkinson Disease Genes by Integrating Genome-Wide Association Study, Expression, and Epigenetic Data Sets	92
Identifying the Distinct Cognitive Phenotypes in Multiple Sclerosis	91
Seizure Cycles in Focal Epilepsy	91
Association of Prenatal Exposure to Antiseizure Medication With Risk of Autism and Intellectual Disability	90
Twenty-Year Change in Severity and Outcome of Ischemic and Hemorrhagic Strokes	90
Effectiveness of Bariatric Surgery vs Community Weight Management Intervention for the Treatment of Idiopathic Intracranial Hypertension	90
Characteristics and Outcomes of Patients With Cerebral Venous Sinus Thrombosis in SARS-CoV-2 Vaccine–Induced Immune Thrombotic Thrombocytopenia	89
Assessment of Emergency Department and Inpatient Use and Costs in Adult and Pediatric Functional Neurological Disorders	88
Estimating the Prevalence of Dementia and Mild Cognitive Impairment in the US	86
Blood Pressure Thresholds and Neurologic Outcomes After Endovascular Therapy for Acute Ischemic Stroke	83
Efficacy of Nilotinib in Patients With Moderately Advanced Parkinson Disease	82
Continuous vs Routine Electroencephalogram in Critically Ill Adults With Altered Consciousness and No Recent Seizure	82
Autoimmune Encephalitis Misdiagnosis in Adults	79

Association of Field Position and Career Length With Risk of Neurodegenerative Disease in Male Former Professional Soccer Players	78
Effect of Ezogabine on Cortical and Spinal Motor Neuron Excitability in Amyotrophic Lateral Sclerosis	78
Prevalence of High-risk Plaques and Risk of Stroke in Patients With Asymptomatic Carotid Stenosis	78
Thrombectomy for Primary Distal Posterior Cerebral Artery Occlusion Stroke	77
Safety and Effectiveness of Long-term Intravenous Administration of Edaravone for Treatment of Patients With Amyotrophic Lateral Sclerosis	77
Characterization of Alzheimer Disease Biomarker Discrepancies Using Cerebrospinal Fluid Phosphorylated Tau and AV1451 Positron Emission Tomography	77
Association of Neighborhood-Level Disadvantage With Cerebral and Hippocampal Volume	77
Prognostic Value of Spreading Depolarizations in Patients With Severe Traumatic Brain Injury	76
Assessment of Demographic, Genetic, and Imaging Variables Associated With Brain Resilience and Cognitive Resilience to Pathological Tau in Patients With Alzheimer Disease	76
Association Between Tumor Necrosis Factor Inhibitor Exposure and Inflammatory Central Nervous System Events	75
Association of NO₂ and Other Air Pollution Exposures With the Risk of Parkinson Disease	75
Association of Disease-Modifying Treatment and Anti-CD20 Infusion Timing With Humoral Response to 2 SARS-CoV-2 Vaccines in Patients With Multiple Sclerosis	74
Risk Factors Associated With Alzheimer Disease and Related Dementias by Sex and Race and Ethnicity in the US	73
Recovery of Consciousness and Functional Outcome in Moderate and Severe Traumatic Brain Injury	72
Emerging Neuroimaging Biomarkers Across Disease Stage in Parkinson Disease	71
Comparison of 3 Treatment Strategies for Medication Overuse Headache	71
Trends in Relative Incidence and Prevalence of Dementia Across Non-Hispanic Black and White Individuals in the United States, 2000-2016	69
Association of Sleep-Disordered Breathing With Alzheimer Disease Biomarkers in Community-Dwelling Older Adults	69
Health Disparities, Inequities, and Social Determinants of Health in Multiple Sclerosis and Related Disorders in the US	69
Antiepileptic Drug Exposure in Infants of Breastfeeding Mothers With Epilepsy	68
Association Between Immunosuppressive Treatment and Outcomes of Cerebral Amyloid Angiopathy–Related Inflammation	67
Association of Donanemab Treatment With Exploratory Plasma Biomarkers in Early Symptomatic Alzheimer Disease	67
Association of NOTCH2NLC Repeat Expansions With Parkinson Disease	67
Clinical Predictors of Neurotoxicity After Chimeric Antigen Receptor T-Cell Therapy	67
Association ofKlotho-VS Heterozygosity With Risk of Alzheimer Disease in Individuals Who CarryAPOE4	66
Comparison Between Rituximab Treatment for New-Onset Generalized Myasthenia Gravis and Refractory Generalized Myasthenia Gravis	65
Prediction of Early Neurological Deterioration in Individuals With Minor Stroke and Large Vessel Occlusion Intended for Intravenous Thrombolysis Alone	64
Immunogenicity and Safety of a Third SARS-CoV-2 Vaccine Dose in Patients With Multiple Sclerosis and Weak Immune Response After COVID-19 Vaccination	64
Biomarker-Based Prediction of Longitudinal Tau Positron Emission Tomography in Alzheimer Disease	64
Direct to Angiography Suite Without Stopping for Computed Tomography Imaging for Patients With Acute Stroke	64
Association of Circadian Abnormalities in Older Adults With an Increased Risk of Developing Parkinson Disease	64
Comparison of Prehospital Scales for Predicting Large Anterior Vessel Occlusion in the Ambulance Setting	63
Association of Daily Step Count and Intensity With Incident Dementia in 78 430 Adults Living in the UK	63
Prediction of Longitudinal Cognitive Decline in Preclinical Alzheimer Disease Using Plasma Biomarkers	62
Assessment of Racial/Ethnic Disparities in Timeliness and Comprehensiveness of Dementia Diagnosis in California	62
Encephalitis Induced by Immune Checkpoint Inhibitors	62
What the Aducanumab Approval Reveals About Alzheimer Disease Research	61
Association of Stress-Related Disorders With Subsequent Neurodegenerative Diseases	60
Omicron-Specific Cytotoxic T-Cell Responses After a Third Dose of mRNA COVID-19 Vaccine Among Patients With Multiple Sclerosis Treated With Ocrelizumab	60
Association of Phosphorylated Tau Biomarkers With Amyloid Positron Emission Tomography vs Tau Positron Emission Tomography	58
Assessment of the Validity of the 2HELPS2B Score for Inpatient Seizure Risk Prediction	58
Addressing Health Disparities Among Minority Populations	58
Evaluating the Safety and Efficacy of Crenezumab vs Placebo in Adults With Early Alzheimer Disease	56
Hypoxic-Ischemic Encephalopathy Evaluated by Brain Autopsy and Neuroprognostication After Cardiac Arrest	56
Findings of Efficacy, Safety, and Biomarker Outcomes of Atabecestat in Preclinical Alzheimer Disease	55
Assessing Brain Capillaries in Coronavirus Disease 2019	55
Association Between Blood Pressure and Later-Life Cognition Among Black and White Individuals	54
Evaluating the Risk of Macrovascular Events and Mortality Among People With Multiple Sclerosis in England	54
Effect of In-Hospital Remote Ischemic Perconditioning on Brain Infarction Growth and Clinical Outcomes in Patients With Acute Ischemic Stroke	53
Association of Rapid Eye Movement Sleep With Mortality in Middle-aged and Older Adults	53
Effect of Methylphenidate on Apathy in Patients With Alzheimer Disease	53
Safety of Early Discontinuation of Antiseizure Medication After Acute Symptomatic Neonatal Seizures	52
Surgical Decompression for Space-Occupying Hemispheric Infarction	52
Association Between Ambient Air Pollution and Amyloid Positron Emission Tomography Positivity in Older Adults With Cognitive Impairment	52
Comparative Effectiveness of Carotid Endarterectomy vs Initial Medical Therapy in Patients With Asymptomatic Carotid Stenosis	52
Pathological Computed Tomography Features Associated With Adverse Outcomes After Mild Traumatic Brain Injury	52
Safety and Efficacy of Semorinemab in Individuals With Prodromal to Mild Alzheimer Disease	51
Assessment of Incidence and Risk Factors of Intracerebral Hemorrhage Among Participants in the Framingham Heart Study Between 1948 and 2016	51
Association of Ischemic Stroke Incidence, Severity, and Recurrence With Dementia in the Atherosclerosis Risk in Communities Cohort Study	50
Long-term Outcomes in Patients With Myelin Oligodendrocyte Glycoprotein Immunoglobulin G–Associated Disorder	50
Outcomes of Intensive Systolic Blood Pressure Reduction in Patients With Intracerebral Hemorrhage and Excessively High Initial Systolic Blood Pressure	49
Association of Amyloid Reduction After Donanemab Treatment With Tau Pathology and Clinical Outcomes	49
Implementation of a Prehospital Stroke Triage System Using Symptom Severity and Teleconsultation in the Stockholm Stroke Triage Study	48
Estimates of the Association of Dementia With US Mortality Levels Using Linked Survey and Mortality Records	48
Development and Validation of the Rasch-Built Overall Amyotrophic Lateral Sclerosis Disability Scale (ROADS)	47
Short-term Psychological Outcomes of Disclosing Amyloid Imaging Results to Research Participants Who Do Not Have Cognitive Impairment	47
Association of Late-Onset Unprovoked Seizures of Unknown Etiology With the Risk of Developing Dementia in Older Veterans	47
Evaluation of a New Criterion for Detecting Prion Disease With Diffusion Magnetic Resonance Imaging	46
Association of Hearing Aids and Cochlear Implants With Cognitive Decline and Dementia	45
Trends in Optic Neuritis Incidence and Prevalence in the UK and Association With Systemic and Neurologic Disease	45
Association of Early Progression Independent of Relapse Activity With Long-term Disability After a First Demyelinating Event in Multiple Sclerosis	45
Research Criteria for the Behavioral Variant of Alzheimer Disease	45
Use of Multimodal Imaging and Clinical Biomarkers in Presymptomatic Carriers of C9orf72 Repeat Expansion	45
Long-term Risk of Parkinson Disease Following Influenza and Other Infections	45
Postmortem Assessment of Olfactory Tissue Degeneration and Microvasculopathy in Patients With COVID-19	45
Distributional Validity and Prognostic Power of the National Institutes of Health Stroke Scale in US Administrative Claims Data	44
Helping the Public Understand Adverse Events Associated With COVID-19 Vaccinations	44
Association of Early-Life Cognitive Enrichment With Alzheimer Disease Pathological Changes and Cognitive Decline	43
Efficacy and Safety of Rituximab for New-Onset Generalized Myasthenia Gravis	43
Association of Brain Atrophy With Disease Progression Independent of Relapse Activity in Patients With Relapsing Multiple Sclerosis	43

Association of Variants in the SPTLC1 Gene With Juvenile Amyotrophic Lateral Sclerosis	43
Assessment of Optimal Patient Selection for Endovascular Thrombectomy Beyond 6 Hours After Symptom Onset	43
Efficacy and Safety of Fenfluramine for the Treatment of Seizures Associated With Lennox-Gastaut Syndrome	43
Association of Racial Residential Segregation Throughout Young Adulthood and Cognitive Performance in Middle-aged Participants in the CARDIA Study	43
Tolerability of Antiseizure Medications in Individuals With Newly Diagnosed Epilepsy	42
Six Action Steps to Address Global Disparities in Parkinson Disease	42
Amyloid-Related Imaging Abnormalities and β-Amyloid–Targeting Antibodies	42
Association of Enzyme-Inducing Antiseizure Drug Use With Long-term Cardiovascular Disease	42
Safety and Efficacy of RimabotulinumtoxinB for Treatment of Sialorrhea in Adults	41
Association of Intensive vs Standard Blood Pressure Control With Magnetic Resonance Imaging Biomarkers of Alzheimer Disease	41
Association of Maintenance Intravenous Immunoglobulin With Prevention of Relapse in Adult Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease	40
Progressive Multifocal Leukoencephalopathy in a Patient With Progressive Multiple Sclerosis Treated With Ocrelizumab Monotherapy	40
Hookworm Treatment for Relapsing Multiple Sclerosis	40
Association Between Intensity of Low-Density Lipoprotein Cholesterol Reduction With Statin-Based Therapies and Secondary Stroke Prevention	40
Association of Glycolysis-Enhancing α-1 Blockers With Risk of Developing Parkinson Disease	40
Serum Glial Fibrillary Acidic Protein Compared With Neurofilament Light Chain as a Biomarker for Disease Progression in Multiple Sclerosis	40
Association Between Common Variants in RBFOX1, an RNA-Binding Protein, and Brain Amyloidosis in Early and Preclinical Alzheimer Disease	40
Paramagnetic Rim Sign in Radiologically Isolated Syndrome	39
Residual Fatigue and Cognitive Deficits in Patients After Leucine-Rich Glioma-Inactivated 1 Antibody Encephalitis	39
Neurologic Prognostication After Cardiac Arrest Using Brain Biomarkers	39
Autologous Hematopoietic Stem Cell Transplant in Multiple Sclerosis	38
Association of Dermatomyositis Sine Dermatitis With Anti–Nuclear Matrix Protein 2 Autoantibodies	38
One-Year Outcome Trajectories and Factors Associated with Functional Recovery Among Survivors of Intracerebral and Intraventricular Hemorrhage With Initial Severe Disability	38
Antiseizure Medication Concentrations During Pregnancy	38
Rate of Recurrent Guillain-Barré Syndrome After mRNA COVID-19 Vaccine BNT162b2	38
General Anesthesia vs Local Anesthesia in Microelectrode Recording–Guided Deep-Brain Stimulation for Parkinson Disease	38
Association Between Prehospital Tranexamic Acid Administration and Outcomes of Severe Traumatic Brain Injury	38
Huntingtin-Lowering Therapies for Huntington Disease	38
Tau Positron Emission Tomographic Findings in a Former US Football Player With Pathologically Confirmed Chronic Traumatic Encephalopathy	37
Cost-effectiveness of Aducanumab and Donanemab for Early Alzheimer Disease in the US	37
A Pooled Analysis of Diffusion-Weighted Imaging Lesions in Patients With Acute Intracerebral Hemorrhage	37
Trends in Reperfusion Therapy for In-Hospital Ischemic Stroke in the Endovascular Therapy Era	37
Durability of Clinical and Quality-of-Life Outcomes of Closed-Loop Spinal Cord Stimulation for Chronic Back and Leg Pain	37
Characteristics of Recurrent Ischemic Stroke After Embolic Stroke of Undetermined Source	37
Comparison of Drug-Eluting Stent With Bare-Metal Stent in Patients With Symptomatic High-grade Intracranial Atherosclerotic Stenosis	37
Association of Plasma p-tau181 and p-tau231 Concentrations With Cognitive Decline in Patients With Probable Dementia With Lewy Bodies	37
Reperfusion Treatment and Stroke Outcomes in Hospitals With Telestroke Capacity	37
SARS-CoV-2 Antibodies in Adult Patients With Multiple Sclerosis in the Amsterdam MS Cohort	36
Prognosis of Asymptomatic Intracranial Stenosis in Patients With Transient Ischemic Attack and Minor Stroke	36
Endovascular Treatment After Stroke Due to Large Vessel Occlusion for Patients Presenting Very Late From Time Last Known Well	36
Assessment of Safety of a Fully Implanted Endovascular Brain-Computer Interface for Severe Paralysis in 4 Patients	35
Association of Elevated Amyloid and Tau Positron Emission Tomography Signal With Near-Term Development of Alzheimer Disease Symptoms in Older Adults Without Cognitive Impairment	35
Risk of Rupture After Intracranial Aneurysm Growth	35
Two-Year-Old Cognitive Outcomes in Children of Pregnant Women With Epilepsy in the Maternal Outcomes and Neurodevelopmental Effects of Antiepileptic Drugs Study	35
Effect of Motor Skill Training in Functional Activities vs Strength and Flexibility Exercise on Function in People With Chronic Low Back Pain	35
Racial and Ethnic Differences in Amyloid PET Positivity in Individuals With Mild Cognitive Impairment or Dementia	35
Intravenous Thrombolysis in Patients With Ischemic Stroke and Recent Ingestion of Direct Oral Anticoagulants	34
Association of Apolipoprotein E ɛ4 Allele With Clinical and Multimodal Biomarker Changes of Alzheimer Disease in Adults With Down Syndrome	34
Association of Rare APOE Missense Variants V236E and R251G With Risk of Alzheimer Disease	34
Anti–SARS-CoV-2 and Autoantibody Profiles in the Cerebrospinal Fluid of 3 Teenaged Patients With COVID-19 and Subacute Neuropsychiatric Symptoms	34
Sex-Specific Association of the X Chromosome With Cognitive Change and Tau Pathology in Aging and Alzheimer Disease	34
Association Between Treatment Progression, Disease Refractoriness, and Burden of Illness Among Hospitalized Patients With Status Epilepticus	34
Direct to Angiography vs Repeated Imaging Approaches in Transferred Patients Undergoing Endovascular Thrombectomy	33
Trends in Mortality Rates Among Medicare Enrollees With Alzheimer Disease and Related Dementias Before and During the Early Phase of the COVID-19 Pandemic	33
Assessment of Recurrent Stroke Risk in Patients With a Carotid Web	33
Prevalence of Incidentally Detected Signs of Intracranial Hypertension on Magnetic Resonance Imaging and Their Association With Papilledema	33
A 5-Decade Analysis of Incidence Trends of Ischemic Stroke After Transient Ischemic Attack	33
Sex Disparities in Enrollment in Recent Randomized Clinical Trials of Acute Stroke	33
Stroke Thrombolysis With Tenecteplase to Reduce Emergency Department Spread of Coronavirus Disease 2019 and Shortages of Alteplase	33
Aggregated Tau Measured by Visual Interpretation of Flortaucipir Positron Emission Tomography and the Associated Risk of Clinical Progression of Mild Cognitive Impairment and Alzheimer Disease	32
DIAPH1 Variants in Non–East Asian Patients With Sporadic Moyamoya Disease	32
Comparison of Mobile Stroke Unit With Usual Care for Acute Ischemic Stroke Management	32
Evaluation of Outcomes Among Patients With Traumatic Intracranial Hypertension Treated With Decompressive Craniectomy vs Standard Medical Care at 24 Months	31
Neurologic Complications of Smallpox and Monkeypox	31
Genetic Testing to Inform Epilepsy Treatment Management From an International Study of Clinical Practice	31
Association Between Intracerebral Hemorrhage and Subsequent Arterial Ischemic Events in Participants From 4 Population-Based Cohort Studies	31
Prediction of Long-term Survival After Status Epilepticus Using the ACD Score	31
Clinicopathologic Features of Oculopharyngodistal Myopathy WithLRP12CGG Repeat Expansions Compared With Other Oculopharyngodistal Myopathy Subtypes	30
Healthy Life-Year Costs of Treatment Speed From Arrival to Endovascular Thrombectomy in Patients With Ischemic Stroke	30
Sexual and Gender Minority Health in Neurology	30
US Food and Drug Administration Approval of Aducanumab—Is Amyloid Load a Valid Surrogate End Point for Alzheimer Disease Clinical Trials?	30
Risk Factors and Prognosis of Early Posttraumatic Seizures in Moderate to Severe Traumatic Brain Injury	30
Divergent Cortical Tau Positron Emission Tomography Patterns Among Patients With Preclinical Alzheimer Disease	29
Association Between Apolipoprotein E ε2 vs ε4, Age, and β-Amyloid in Adults Without Cognitive Impairment	29
Cancer Risk in Children of Mothers With Epilepsy and High-Dose Folic Acid Use During Pregnancy	29
Diagnosis of Progressive Multiple Sclerosis From the Imaging Perspective	28
Rates of Incidental Findings in Brain Magnetic Resonance Imaging in Children	28
Evaluating Rates of Recurrent Ischemic Stroke Among Young Adults With Embolic Stroke of Undetermined Source	28
Suicidality Risk of Newer Antiseizure Medications	28
Trends in Antihypertensive Medication Use Among Individuals With a History of Stroke and Hypertension, 2005 to 2016	28
Association of Endovascular Thrombectomy vs Medical Management With Functional and Safety Outcomes in Patients Treated Beyond 24 Hours of Last Known Well	27
Association Between Alberta Stroke Program Early Computed Tomography Score and Efficacy and Safety Outcomes With Endovascular Therapy in Patients With Stroke From Large-Vessel Occlusion	27
Prognosis of Cryptogenic Stroke With Patent Foramen Ovale at Older Ages and Implications for Trials	27
Assessment of Telestroke Capacity in US Hospitals	27
Risk of Persistent Disability in Patients With Pediatric-Onset Multiple Sclerosis	27
Opportunities for Prevention of Concussion and Repetitive Head Impact Exposure in College Football Players	27
Factors Contributing to Major Neurological Complications From Vein of Galen Malformation Embolization	26
Effects of Antiplatelet Therapy After Stroke Caused by Intracerebral Hemorrhage	26
Microbleeds and the Effect of Anticoagulation in Patients With Embolic Stroke of Undetermined Source	26
Framework for Clinical Trials in Cerebral Small Vessel Disease (FINESSE)	26
Association of APOE Genotypes and Chronic Traumatic Encephalopathy	26
Time for a New Image of Parkinson Disease	25
Monitoring Clinical Course and Treatment Response in Chronic Inflammatory Demyelinating Polyneuropathy During Routine Care	25
Assessment of Risk Factors and Early Presentations of Parkinson Disease in Primary Care in a Diverse UK Population	25
Trends Among Rural and Urban Medicare Beneficiaries in Care Delivery and Outcomes for Acute Stroke and Transient Ischemic Attacks, 2008-2017	25